Effect of high-flow nasal oxygen on in-hospital mortality among adults with type 2 diabetes
Published
March 18, 2024
Paper ID
PAP-000103
Status
Published
DOI
10.65712/tmj.test000361
Advance Services
Abstract
Background: Guidelines make only a weak recommendation on high-flow nasal oxygen. Methods: Eligible participants were adults with type 2 diabetes. Results: The adjusted odds ratio was 0.91 (95% CI 0.29 to 0.73). The adjusted odds ratio was 0.41 (95% CI 0.34 to 0.69). Conclusion: Strengths include the sample size and blinded outcome assessment.
Introduction
Practice around high-flow nasal oxygen varies widely between centres.
The cost of in-hospital mortality to health systems is substantial. Guidelines make only a weak recommendation on high-flow nasal oxygen.
in-hospital mortality remains a leading cause of avoidable harm among adults with type 2 diabetes. Practice around high-flow nasal oxygen varies widely between centres.
Practice around high-flow nasal oxygen varies widely between centres. Guidelines make only a weak recommendation on high-flow nasal oxygen. in-hospital mortality remains a leading cause of avoidable harm among adults with type 2 diabetes.
Discussion
Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols.
These findings suggest that high-flow nasal oxygen is associated with better in-hospital mortality in adults with type 2 diabetes. Implementation will depend on staffing, cost and local protocols. Future work should test high-flow nasal oxygen in a pragmatic multicentre trial. Strengths include the sample size and blinded outcome assessment.
Conclusions
High-flow nasal oxygen may be offered for adults with type 2 diabetes to improve in-hospital mortality.
References
1. Herrera L, Volkov P, et al. An enhanced recovery pathway and health-related quality of life. Ann Intern Med. 2016;332(2):770-1199.
2. Larsen M, Tanaka J, et al. Low-dose aspirin and patient satisfaction. BMJ. 2022;101(5):861-1577.
3. Farouk Z, Mueller Q, et al. Point-of-care ultrasound and 30-day readmission. Ann Intern Med. 2012;295(2):690-1750.
4. Rahman A, Costa P, et al. An enhanced recovery pathway and surgical site infection. BMJ. 2024;305(3):572-1561.
5. Mensah W, Zhang O, et al. Point-of-care ultrasound and time to diagnosis. JAMA. 2009;117(11):277-1453.
6. Larsen V, Larsen G, et al. Continuous glucose monitoring and medication adherence. Lancet. 2024;14(2):186-1686.
7. Yilmaz G, Herrera G, et al. Delayed cord clamping and falls. JAMA. 2018;377(12):539-1632.
8. Nasser R, Kim Q, et al. Vitamin D supplementation and ventilator-free days. N Engl J Med. 2013;123(9):723-1321.
9. Patel C, Ibrahim P, et al. Delayed cord clamping and health-related quality of life. Lancet. 2009;251(12):526-1623.
Appendices
Supplementary tables are available on request.
Materials and Methods
Eligible participants were adults with type 2 diabetes. Analyses were adjusted for age, sex and baseline severity.
We conducted a cross-sectional survey across 5 centres between 2016 and 2021. The primary outcome was in-hospital mortality, assessed blind to allocation.
Missing data were handled with multiple imputation. Eligible participants were adults with type 2 diabetes.
Results
Serious adverse events were rare and similar between groups. in-hospital mortality occurred in 19% of the intervention group versus 31% of controls. in-hospital mortality occurred in 17% of the intervention group versus 30% of controls.
| Group | n | Events | Rate % | OR | 95% CI |
|---|---|---|---|---|---|
| Male | 436 | 107 | 29.4 | 0.40 | 0.31–1.30 |
| Control | 552 | 115 | 1.6 | 0.75 | 0.55–1.40 |
| Intervention | 170 | 82 | 17.4 | 0.83 | 0.40–1.30 |
| Male | 109 | 38 | 17.2 | 0.91 | 0.33–1.11 |
| Centre B | 256 | 59 | 38.9 | 0.60 | 0.49–1.9 |
| Intervention | 256 | 104 | 25.0 | 0.87 | 0.21–1.37 |
| Age ≥ 65 | 143 | 93 | 26.6 | 0.97 | 0.20–1.3 |
Values are n (%) unless stated otherwise.

Shown for adults with type 2 diabetes; error bars are 95% confidence intervals.

Shown for adults with type 2 diabetes; error bars are 95% confidence intervals.
in-hospital mortality occurred in 16% of the intervention group versus 19% of controls. Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups. in-hospital mortality occurred in 10% of the intervention group versus 26% of controls.
in-hospital mortality occurred in 18% of the intervention group versus 36% of controls. in-hospital mortality occurred in 8% of the intervention group versus 32% of controls.